Candriam Luxembourg S.C.A. trimmed its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 4.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 515,000 shares of the company’s stock after selling 25,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Kura Oncology were worth $7,880,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. California Public Employees Retirement System raised its holdings in shares of Kura Oncology by 109.2% during the fourth quarter. California Public Employees Retirement System now owns 49,167 shares of the company’s stock valued at $752,000 after purchasing an additional 25,667 shares during the last quarter. Alps Advisors Inc. purchased a new position in shares of Kura Oncology during the fourth quarter valued at approximately $512,000. Iguana Healthcare Management LLC purchased a new position in shares of Kura Oncology during the third quarter valued at approximately $1,346,000. California State Teachers Retirement System raised its holdings in shares of Kura Oncology by 24.5% during the third quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock valued at $471,000 after purchasing an additional 6,200 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its holdings in shares of Kura Oncology by 61.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 39,200 shares of the company’s stock valued at $587,000 after purchasing an additional 14,900 shares during the last quarter. 63.10% of the stock is owned by hedge funds and other institutional investors.

Shares of Kura Oncology, Inc. (NASDAQ:KURA) opened at $18.85 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 13.48 and a quick ratio of 13.48. Kura Oncology, Inc. has a 12-month low of $5.90 and a 12-month high of $21.00.

Several research analysts have recently weighed in on KURA shares. Wedbush started coverage on shares of Kura Oncology in a report on Wednesday, December 20th. They set an “outperform” rating and a $19.00 price objective for the company. Zacks Investment Research cut shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. BidaskClub lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Oppenheimer set a $18.00 target price on shares of Kura Oncology and gave the company a “buy” rating in a research report on Monday, December 11th. Finally, Citigroup boosted their target price on shares of Kura Oncology from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $18.08.

ILLEGAL ACTIVITY NOTICE: This article was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://theolympiareport.com/2018/02/15/candriam-luxembourg-s-c-a-decreases-stake-in-kura-oncology-inc-kura.html.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA).

Institutional Ownership by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.